6 stories mentioning IMMXUpdated 8d ago
Every FINWIRES story that references IMMX, newest first.
Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.94, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.79, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks were declining premarket Thursday, with the iShares Biotechnology ETF (IBB) 1% lower and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.Immix Biopharma (IMMX) shares were up more than 6% after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.Nanobiotix (NBTX) launched a global follow-on offering of 75 million euros ($87.2 million), the clinical-stage biotechnology company said. Nanobiotix stock was down more than 5% pre-bell.Relay Therapeutics (RLAY) shares were up more than 10% after the company said it priced a public offering of 22.9 million common shares at $12 each.
Healthcare stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.1%.Immix Biopharma (IMMX) shares were nearly 8% higher after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.
(Updated to keep price target unchanged).(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $8.57, Change: $-0.04, Percent Change: -0.41%
Mizuho Adjusts Price Target on Immix Biopharma to $15 From $10, Maintains Outperform Rating
